To unpack what the new policy means for drug developers, Fierce Biotech’s Darren Incorvaia sat down with Torrey Cope, a ...

Dianthus Therapeutics and Boehringer Ingelheim headlined the latest round of licensing d | Dianthus and Boehringer Ingelheim ...

Teladoc has long said that insurance coverage for its therapy services could help attract more people to the BetterHelp ...

Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting previously difficult populations, with recent clinical data demonstrating high response ...

Deals: Novo Nordisk is set to buy a blood disease drug from Omeros for up to $2.1 billion. Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion. Boehringer Ingelhei ...

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...

Under the terms of the deal, Gilead will put down $120 million in an upfront payment and will promise up to $1.52 billion in ...

Refabric and Homster, two artificial intelligence-driven startups supported by Türk Telekom's Pilot accelerator program, took ...

Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

Graphs, Data, Perspectives’, Udit Misra looks at the lowered economic competitiveness of Europe, which essentially ran the ...

ZETA’s digital solutions enable pharmaceutical and biotech companies to accelerate innovation, streamline operations, and ...

Agentic AI technology can free up human beings from repetitive tasks that can be automated, leaving people free to apply ...